Loading...

Scott Thomas, PhD

Title(s)Associate Researcher, Medicine
SchoolSchool of Medicine
Phone415-476-5783
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPostdoctoral StudiesGraduate Division
    University of California, DavisPhDBiochemistry, Cell, and Molecular Biology

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 01 08; 8(1):92. PMID: 29311658.
      View in: PubMed
    2. Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017 Dec 26; 8(69):114156-114172. PMID: 29371976.
      View in: PubMed
    3. Terranova-Barberio M, Thomas S, Munster PN. Host histone acetylation unlocks HDAC inhibitor potential. Oncotarget. 2017 Dec 05; 8(63):106161-106162. PMID: 29290932.
      View in: PubMed
    4. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. PMID: 28893315.
      View in: PubMed
    5. Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Plast Reconstr Surg. 2017 Sep; 140(3):537-544. PMID: 28841614.
      View in: PubMed
    6. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. PMID: 28790114.
      View in: PubMed
    7. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239. PMID: 28221861.
      View in: PubMed
    8. Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016 06; 8(6):705-19. PMID: 27197539.
      View in: PubMed
    9. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 05; 27(5):947-52. PMID: 26903311; PMCID: PMC4843187 [Available on 05/01/17].
      View in: PubMed, PubMed Central
    10. Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015 Feb 25; 17:26. PMID: 25848915; PMCID: PMC4367983.
      View in: PubMed, PubMed Central
    11. Park J, Thomas S, Munster PN. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015; 7(4):641-52. PMID: 26111034.
      View in: PubMed
    12. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013 Oct; 12(10):2078-87. PMID: 23939379; PMCID: PMC3821775.
      View in: PubMed, PubMed Central
    13. Thomas S, Thurn KT, Raha P, Chen S, Munster PN. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 2013; 8(7):e68973. PMID: 23874830; PMCID: PMC3711340.
      View in: PubMed, PubMed Central
    14. Raha P, Thomas S, Munster PN. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011 Aug; 3(4):451-70. PMID: 22126205.
      View in: PubMed
    15. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 07; 104(12):1828-35. PMID: 21559012; PMCID: PMC3111195.
      View in: PubMed, PubMed Central
    16. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011 Nov; 130(2):437-47. PMID: 21298336; PMCID: PMC3760725.
      View in: PubMed, PubMed Central
    17. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011 Feb; 7(2):263-83. PMID: 21345145; PMCID: PMC3127396.
      View in: PubMed, PubMed Central
    18. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 06; 101(7):1044-50. PMID: 19738609; PMCID: PMC2768109.
      View in: PubMed, PubMed Central
    19. Thomas S, Munster PN. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009 Aug 08; 280(2):184-91. PMID: 19185986.
      View in: PubMed
    20. Thomas S, Kaplan KB. A Bir1p Sli15p kinetochore passenger complex regulates septin organization during anaphase. Mol Biol Cell. 2007 Oct; 18(10):3820-34. PMID: 17652458.
      View in: PubMed
    21. Gillis AN, Thomas S, Hansen SD, Kaplan KB. A novel role for the CBF3 kinetochore-scaffold complex in regulating septin dynamics and cytokinesis. J Cell Biol. 2005 Dec 05; 171(5):773-84. PMID: 16330709; PMCID: PMC2171293.
      View in: PubMed, PubMed Central
    22. Rodrigo-Brenni MC, Thomas S, Bouck DC, Kaplan KB. Sgt1p and Skp1p modulate the assembly and turnover of CBF3 complexes required for proper kinetochore function. Mol Biol Cell. 2004 Jul; 15(7):3366-78. PMID: 15090617.
      View in: PubMed
    23. Thomas S, Yen TY, Macher BA. Eukaryotic glycosyltransferases: cysteines and disulfides. Glycobiology. 2002 Feb; 12(2):4G-7G. PMID: 11954545.
      View in: PubMed
    24. Holmes EH, Yen TY, Thomas S, Joshi R, Nguyen A, Long T, Gallet F, Maftah A, Julien R, Macher BA. Human alpha 1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites. J Biol Chem. 2000 Aug 11; 275(32):24237-45. PMID: 10816554.
      View in: PubMed
    Scott's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (171) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (22) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑